Stocktoria
Revolution Medicines, Inc. RVMD
Revolution Medicines, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.6M | $35.4M | $29.4M | $43.0M | $50.0M |
| R&D expense | $987.3M | $592.2M | $423.1M | $253.1M | $186.9M | $132.3M | $91.8M |
| Operating income | -$1.2B | -$689.5M | -$487.2M | -$258.3M | -$188.0M | -$110.7M | -$54.1M |
| Interest expense | — | — | — | $0 | $12,000 | $71,000 | $106,000 |
| Income tax | $0 | -$753,000 | -$3.5M | -$420,000 | $0 | -$371,000 | -$4.4M |
| Net income | -$1.1B | -$600.1M | -$436.4M | -$248.7M | -$187.1M | -$108.2M | -$47.7M |
| EPS (diluted) | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 | $-2.01 | — |
| Operating cash flow | -$897.7M | -$557.4M | -$350.6M | -$224.4M | -$147.2M | -$100.1M | -$49.6M |
| Free cash flow | -$913.7M | -$567.7M | -$358.3M | -$235.2M | -$153.7M | -$103.0M | -$52.2M |
| Cash & equivalents | $383.7M | $543.1M | $696.1M | $161.4M | $108.5M | $104.3M | $16.7M |
| Total assets | $2.4B | $2.6B | $2.1B | $811.9M | $738.0M | $567.4M | $220.5M |
| Total liabilities | $723.2M | $293.1M | $235.5M | $126.7M | $135.4M | $92.7M | $68.0M |
| Shareholders' equity | $1.6B | $2.3B | $1.8B | $685.2M | $602.6M | $474.7M | -$152.6M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | — | -100.0% | -67.3% | +20.4% | -31.6% | -14.1% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.